AngioDynamics (ANGO) to Release Earnings on Wednesday

AngioDynamics (NASDAQ:ANGO) is anticipated to release its earnings data before the market opens on Wednesday, April 2nd. Analysts expect AngioDynamics to post earnings of ($0.13) per share and revenue of $70.30 million for the quarter. AngioDynamics has set its FY 2025 guidance at -0.380–0.340 EPS and its FY25 guidance at ($0.38)-($0.34) EPS.Investors that wish to register for the company’s conference call can do so using this link.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. The firm had revenue of $72.90 million for the quarter, compared to analysts’ expectations of $70.93 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The business’s revenue was down .1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.05) earnings per share. On average, analysts expect AngioDynamics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AngioDynamics Stock Performance

Shares of NASDAQ ANGO opened at $9.50 on Monday. AngioDynamics has a 52-week low of $5.47 and a 52-week high of $13.50. The business has a fifty day moving average of $10.41 and a two-hundred day moving average of $8.81. The stock has a market cap of $384.43 million, a PE ratio of -1.69 and a beta of 0.56.

Insiders Place Their Bets

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the firm’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the completion of the sale, the senior vice president now owns 41,817 shares in the company, valued at approximately $514,767.27. This trade represents a 8.85 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 5.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright upped their price objective on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, January 10th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.